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Abstract 
The truncated chromosome 22 that results from the reciprocal translocation t(9;22)(q34;q11) is known as the Phila‑
delphia chromosome (Ph) and is a hallmark of chronic myeloid leukemia (CML). In leukemia cells, Ph not only impairs 
the physiological signaling pathways but also disrupts genomic stability. This aberrant fusion gene encodes the 
breakpoint cluster region‑proto‑oncogene tyrosine‑protein kinase (BCR‑ABL1) oncogenic protein with persistently 
enhanced tyrosine kinase activity. The kinase activity is responsible for maintaining proliferation, inhibiting differentia‑
tion, and conferring resistance to cell death. During the progression of CML from the chronic phase to the accelerated 
phase and then to the blast phase, the expression patterns of different BCR‑ABL1 transcripts vary. Each BCR‑ABL1 
transcript is present in a distinct leukemia phenotype, which predicts both response to therapy and clinical outcome. 
Besides CML, the Ph is found in acute lymphoblastic leukemia, acute myeloid leukemia, and mixed‑phenotype acute 
leukemia. Here, we provide an overview of the clinical presentation and cellular biology of different phenotypes of Ph‑
positive leukemia and highlight key findings regarding leukemogenesis.
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Background
Leukemia has among the highest mortalities of any cancer 
[1]. Chronic myeloid leukemia (CML) accounts for 15%–
20% of all adult leukemias [2]. The Philadelphia chromo-
some (Ph) is the truncated chromosome 22 generated by 
the reciprocal translocation t(9;22)(q34;q11) and was first 
identified in 1960 in a patient with CML [3]. Translocation 
of the proto-oncogene tyrosine-protein kinase (ABL1) 
gene located on chromosome 9 to the breakpoint cluster 
region (BCR) gene located on chromosome 22 results in a 
BCR-ABL1 fusion gene on the Ph [4, 5]. Three BCR-ABL1 
fusion gene hybrids encode BCR-ABL1 protein isoforms 
p210, p190, and p230, which have persistently enhanced 
tyrosine kinase (TK) activity. These aberrantly activated 
kinases disturb downstream signaling pathways, causing 
enhanced proliferation, differentiation arrest, and resist-
ance to cell death [6, 7]. Tyrosine kinase inhibitors (TKIs) 
targeting the BCR-ABL1 protein are the most successful 
targeted therapy for Ph-positive leukemia. However, ther-
apeutic resistance and disease progression are the current 
barriers to improve the prognosis of patients with Ph-
positive leukemia [8–10]. Leukemia stem cells and BCR-
ABL kinase domain mutations may be the keys to solve 
these problems [11]. The Ph is not limited to CML; it is 
also detected in cases of acute myeloid leukemia (AML) 
[12, 13], acute lymphoblastic leukemia (ALL; almost all of 
which are B-cell ALL, rarely T-cell ALL) [14], and mixed-
phenotype acute leukemia (MPAL) [15–17]. The presence 
of the Ph results in patients with different leukemia phe-
notypes having substantially different prognoses. In addi-
tion, other concurrent genomic abnormalities are more 
common in leukemia cells with Ph than in those without. 
These genomic variations, in combination with BCR-
ABL1 transcripts, play an important role during leukemo-
genesis [18–20].
However, the extent of the occurrence of the Ph and 
the types of BCR-ABL1 transcripts found in different 
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leukemia phenotypes, the exact role of the translocation 
in leukemogenesis, and the culprit of therapeutic resist-
ance are still not fully elucidated. Here, we review the 
current understanding of this topic.
The Ph, BCR‑ABL1 fusion gene, and BCR‑ABL hybrid 
protein
Molecular investigation into the Ph observed in CML 
revealed a consistent genomic recombination between 
two genes—BCR on the long arm of chromosome 22 
and ABL1 on the long arm of chromosome 9—result-
ing in their juxtaposition, which generates the BCR-
ABL1 fusion gene [21]. The location of the BCR and 
ABL1 genomic breakpoints is highly variable [22], but 
the recombination usually involves fusion of intron 1, 
intron 13/14, or exon 19 of BCR with a 140-kb region of 
ABL1 between exons 1b and 2 (Fig.  1a). Referred to as 
p210BCR-ABL1, the fusion of BCR exon 13 and ABL1 exon 
2 (e13a2) or e14a2 constitutes the major BCR-ABL1 tran-
script (M-BCR, originally referred to as b2a2 and b3a2). 
Both transcripts result in a hybrid 210-kDa protein. 
p210BCR-ABL1 is most commonly detected in CML and 
occasionally in ALL or AML. p190BCR-ABL1 (e1a2) con-
stitutes the minor BCR-ABL1 transcript (m-BCR), which 
encodes a hybrid 190-kDa protein. p190BCR-ABL is com-
monly detected in B-cell ALL (B-ALL) and occasionally 
in AML but is rarely observed in CML [7]. p230BCR-ABL1 
(e19a2), also known as the μ BCR-ABL1 transcript 
(μ-BCR), encodes a hybrid 230-kDa protein. p230BCR-ABL1 
is generated by the fusion of almost the entire BCR gene 
with the ABL1 gene and is considered a molecular diag-
nostic marker for neutrophilic-chronic myeloid leukemia 
(CML-N) [23].
The BCR-ABL1 protein in CML contains several 
domains from both BCR and ABL1. The domains from 
BCR include an N-terminal coiled-coil domain (CC; 
amino acids 1–63), a Ser/Thr kinase domain containing a 
docking site (phosphorylated tyrosine 177, Y177) for the 
adaptor protein growth factor receptor-bound protein 2 
(GRB2) [24, 25], and a ras homolog gene family/Guanine 
nucleotide exchange factors (Rho/GEF) kinase domain 
(amino acids 298–413) [26], whereas the domains from 
Fig. 1 The structure of the breakpoint cluster region (BCR)‑proto‑oncogene tyrosine‑protein kinase (ABL1) gene and protein. a The BCR‑ABL1 fusion 
gene consists of the 5′ end of the BCR gene located at 22q11 and the 3′ end of the ABL1 gene located at 9q34. The breakpoints of the translocation 
usually involve the intron 13 or 14 of BCR, named major breakpoint (M‑BCR), intron 1 of BCR, named minor breakpoint (m‑BCR), and exon 19 of BCR, 
named μ breakpoint (μ‑BCR). For ABL1, the breakpoint always involves the region between exons 1b and 2. b The BCR‑ABL1 protein contains the 
Ser/Thr kinase domain and the Rho/GEF domain of BCR and the src homology (SH) domains, nuclear localization signal (NLS), and actin‑binding 
domains from ABL1. The SH1 kinase domain is the target of imatinib. The different breakpoints that generate the p230, p210, and p190 isoforms are 
shown
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ABL1 include src homology (SH) domains (SH1/SH2), 
a proline-rich domain, and DNA- and actin-binding 
domains. Although different transcripts encode differ-
ent proteins, a common feature of all the hybrid proteins 
(p210/190/230) is the constitutively active protein kinase 
activity compared to wild-type ABL1 (Fig. 1b).
The N-terminal CC domain and Y177 of BCR are essen-
tial for the activation of ABL1 kinase [27, 28]. Targeting 
the CC domain to disrupt the tetramerization of BCR-
ABL1 reduces its kinase activity and increases sensitivity 
to the TKI imatinib mesylate (imatinib, also known by the 
trade names Gleevec or Glivec) [29, 30], thus indicating 
that inhibition of tetramerization can contribute to over-
coming imatinib resistance. In CML, Y177 plays a critical 
role in leukemic cell progenitor expansion, proliferation, 
and survival. Mutation of the GRB2-binding site at Y177 
in p210BCR-ABL1 fails to induce a CML-like disease [24] 
and enhances sensitivity to imatinib by inhibiting RAS 
and protein kinase B (PKB, also named AKT) activation 
in CML [31]. These results show that Y177 is essential 
for transformation of CML by BCR-ABL1, and that it has 
potential as a target for overcoming imatinib resistance. 
The Rho/GEF protein plays a major role in activating dif-
ferentiation in BCR-ABL1-induced leukemogenesis [32]. 
Inhibition of Rho kinase suppresses DNA synthesis in 
BCR-ABL1-transfected cells and also inhibits the prolif-
eration and survival of CML progenitor cells [33, 34].
ABL1 protein, one of the non-receptor TKs, is present 
throughout hematopoietic development, with declining 
levels during myeloid maturation. The autophosphoryla-
tion site in the activation loop of its SH1 domain con-
stitutes a switch between the inactive and active kinase 
conformation as it conjugates adenosine triphosphate 
(ATP) [35]. Imatinib and other kinase inhibitors com-
pete with ATP to bind the autophosphorylation site, 
blocking the downstream signaling pathway [36]. In the 
“closed” conformation, the SH2 domain inhibits ABL1 
activity, whereas in the “open” conformation, it promotes 
ABL1 activation through binding to the C-terminal of 
the SH1 domain [37]. Importantly, docking of the SH2 
domain to the C-lobe of the kinase is controlled by the 
myristate moiety at the N-terminal of the SH3 domain. 
N-terminal myristoyl modification of the SH3 domain 
of ABL1 binds to the SH1 domain (the kinase domain) 
and induces conformational changes that allow the SH2 
and SH3 domains to dock onto it [38, 39]. Mutant SH3 
domain of ABL1 (exon 1b) with a blocked myristate-
binding site shows strongly deregulated TK activity [38]. 
Also, blocking the myristate-binding site completely 
abolished leukemogenesis in mice and increased the sen-
sitivity of imatinib-resistant BCR-ABL1-bearing mutants 
to TKI inhibition [40, 41]. These findings suggest that 
the myristate-binding site of the SH3 domain of ABL1 
is a potential novel allosteric target for pharmacologic 
intervention.
Ph in different phenotypes of leukemia
Cml
The BCR-ABL1 fusion gene is a hallmark of CML. Three 
discrete clinical stages are defined for CML: the chronic 
phase (CML-CP), the accelerated phase (CML-AP), and 
the blast crisis (CML-BC). Without therapeutic inter-
vention, the disease follows a natural progression from 
relatively benign CML-CP, through CML-AP, to termi-
nal CML-BC. The phenotype of CML-BC can be myeloid 
or lymphoid or, in rare cases, both. Myeloid BC is more 
commonly observed than lymphoid BC. In lymphoid BC, 
the predominant lineage is B-cell, representing about 
30% of cases [42].
Most CML patients have M-BCR transcripts with 
b14a2 (55%) or b13a2 (40%) junctions (p210BCR-ABL1). 
In 5% of CML cases, both b13a2 and b14a2 transcripts 
are detected [43, 44]. However, the e1a2 (p190BCR-ABL1) 
transcript is frequently present at a low level in patients 
with p210BCR-ABL1-positive leukemia [45]. Approximately 
52% of Ph-positive CML cases co-express p210BCR-ABL1 
and p190BCR-ABL1 transcripts, with the other 48% exclu-
sively expressing p210BCR-ABL1 [44]. All CML-BC patients 
co-express both transcripts [44]. Further details were 
provided in a study of 250 Mexican Ph-positive CML 
patients, which found that 90.4% of patients expressed 
p210BCR-ABL1, and approximately 7% of patients with 
p210BCR-ABL1 expressed both isoforms (b3a2/b2a2); how-
ever, co-expression of p190/p210BCR-ABL1 was seen in only 
5% of patients [46]. Nevertheless, the prognosis for CML 
patients who co-express two or all p190/210/230BCR-ABL1 
transcripts is poor [46]. Consistently, CML patients who 
co-express p210/p190BCR-ABL1 have considerably higher 
white blood cell (WBC) and blast cell counts at any time 
of testing, including diagnosis, than patients who express 
only p210BCR-ABL1 [44].
The position of the BCR breakpoint is also associated 
with prognosis. M-BCR rearrangement is predictive of 
response to therapy [47], whereas the presence of a dou-
ble Ph indicates a poor prognosis [42]. However, no sig-
nificant survival difference was found between patients 
with b13a2 and those with b14a2 mRNA junctions [48].
Acute lymphoblastic leukemia
BCR-ABL1 is not restricted to CML. It is also present 
in 11%–29% of ALL patients [49] but is relatively rare 
in childhood ALL (1%–3%) [50]. BCR-ABL1 presence 
in ALL patients increases with age [51] and has been 
reported to be as high as 50% in patients 60  years of 
age or older [52]. With few exceptions, Ph-positive ALL 
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patients are diagnosed with B-ALL [53–55], and most 
cases of Ph-positive ALL express the p190BCR-ABL1 tran-
script. The p210BCR-ABL1 transcript is detected in 30% of 
adult and 20% of childhood patients with Ph-positive 
ALL [43, 45, 56–58]. The BCR-ABL1 variant e3a2 (exon 
3 of BCR and exon 2 of ABL1) can also be detected in 
cases of Ph-positive ALL, which is similar to ALL with 
p190BCR-ABL1 transcript [59].
Prognosis of both adults and children with Ph-positive 
ALL treated with standard chemotherapy is very poor, 
with less than 5% of adults being cured [55, 60]. Fortu-
nately, the combination of chemotherapy with the TKI 
imatinib has remarkable efficacy on newly diagnosed Ph-
positive ALL, achieving a complete remission rate of 95% 
and a patient survival rate of 55% at 3 years [61].
Acute myeloid leukemia
BCR-ABL1 transcripts are rarely found in AML. Less 
than 1.5% of AML patients harbor the BCR-ABL1 fusion 
gene [62–64]. Ph-positive AML is cytogenetically indis-
tinguishable from Ph-positive CML, but molecular 
studies show that, in 50% of cases, the breakpoint on 
chromosome 22 in Ph-positive AML is different from 
those very consistently found in CML [65]. Furthermore, 
studies have confirmed that BCR-ABL1-positive AML is 
a unique acute leukemia with some features distinct from 
myeloid CML-BC. These features include less marked 
splenomegaly, fewer peripheral basophiles, and a lower 
myeloid/erythroid ratio, and bone marrow cellularity [64] 
compared with myeloid CML-BC. In addition, the loss 
within the immunoglobulin genes (deletion of 14q32) in 
some cases of de novo Ph-positive AML can distinguish 
it from myeloid CML-BC [66]. However, the median sur-
vivals of Ph-positive AML and myeloid CML-BC patients 
are similar (9 vs. 7 months, P = 0.54) [64].
Mixed‑phenotype acute leukemia
The Ph is one of the most frequent aberrant cytoge-
netic findings in MPAL. The World Health Organiza-
tion (WHO) defines MPAL as acute leukemia with a 
mixed phenotype containing two morphologically and 
immunophenotypically distinct populations of blasts or 
showing a single blast cell population expressing mixed 
phenotypic markers [67]. Many of these cases have a 
dimorphic population of blasts, with the majority being 
of B-lymphoid/myeloid lineage (59%–60%), followed by 
T-lymphoid/myeloid (32%–35%), T-/B-lymphoid (4%), 
and trilineage (2%–4%) [16, 68]. Ph-positive MPAL is 
defined as acute leukemia meeting the criteria for MPAL 
in which the blasts also have a detectable Ph or BCR-
ABL1 fusion transcript. The frequency of Ph-positive 
MPAL is 17%–35% in adult MPAL patients, whereas 
studies of pediatric patients report a much lower rate of 
3% [69, 70]. No obvious difference was found between 
the BCR-ABL1 transcript types expressed in adult cases 
[71, 72], but 30% of cases have additional chromosomal 
aberrations [72]. Importantly, compared with other 
phenotypes of leukemia, Ph-positive MPAL has a much 
worse outcome [16, 68]. Studies of Ph-positive MPAL are 
rare, and there is no consensus on the most appropriate 
therapy for this subtype. Although TKIs have improved 
the prognosis of Ph-positive MPAL, adult patients are 
still considered for hematopoietic stem cell (HSC) trans-
plantation during the first remission.
What role does Ph play in leukemogenesis?
The BCR-ABL1 fusion protein was first indicated as 
the crucial driver of CML in mouse studies, which 
showed that expression of p210BCR-ABL1 in the bone 
marrow caused a CML-like disease. The progression of 
p210BCR-ABL1-associated disease in transgenic mice is 
consistent with the apparent indolence of human CML-
CP [73, 74]. Expression of p190BCR-ABL1 at a level similar 
to that in the p210BCR-ABL1-transgenic model results in 
a clinically distinct condition. Voncken et  al. [75] dem-
onstrated the development of de novo B-cell leukemia 
in mice exclusively transgenic for p190BCR-ABL1, with a 
relatively short period of latency. Furthermore, Castel-
lanos et  al. [76] created an in-frame fusion of p190BCR-
ABL1 that mimics the human chromosomal translocation 
by homologous recombination in embryonic stem cells. 
The chimeric mice generated with the mutant embry-
onic stem cells systematically developed B-ALL, which 
was detected with elevated TK activity [77]. The TKI 
imatinib, the first agent targeting the TK activity of BCR-
ABL1 protein, has become the first-line therapy for all 
patients with Ph-positive CML; it is also an indispensa-
ble therapy for Ph-positive ALL. Imatinib has changed 
the prognosis of CML radically over the last 15 years and 
improved the overall survival of ALL patients.
In addition to its TK activity, the SH2 domain of BCR-
ABL1 is also required for induction of CML-like disease 
in mice, but, interestingly, SH2 is not required for lym-
phoid leukemogenesis [78]. BCR-ABL1 with deleted SH2 
or the R1057K mutant on SH2 of p210BCR-ABL1 retains 
the ability to induce a fatal myeloproliferative disorder 
(MPD) with an extended latency [79]. Consistently, in 
cells transfected with SH2-mutated BCR-ABL1 or BCR-
ABL1, the B-lymphoid expansion was diminished, sug-
gesting that the BCR-ABL1-induced MPD suppresses 
B-lymphoid expansion [79].
Pathways associated with BCR‑ABL1
The transforming activity of BCR-ABL1 is due to its 
constitutive TK activity, which contributes to the main-
tenance of cell proliferation, inhibits differentiation, and 
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promotes resistance to cell death. BCR-ABL1 kinase 
hyperactivity results in the activation of signaling path-
ways and deregulation of cellular processes [80]. Most 
of these pathways have been demonstrated in CML and 
ALL mouse models. The main pathways associated with 
BCR-ABL1 activity are presented in Fig. 2.
The JAK2/STAT pathway
Activation of Janus kinase (JAK)1–3 [81] and signal trans-
ducers and activators of transcription (STAT)1, 3, 5, and 
6 [81, 82] has been confirmed experimentally in p190/
p210BCR-ABL1-positive leukemia. JAK1–3 activation is 
mediated by the interaction of BCR-ABL1 with cytokine 
receptors [83]. BCR-ABL1 kinase directly enhances 
JAK2/STAT activation to promote cell growth/survival 
in CML models [84, 85], and it requires an intact JAK2/
STAT5 pathway to enable oncogenic transformation 
[83]. JAK3 expression is limited to hematopoietic cells, 
and JAK3-knockout mice have developmental defects 
in lymphoid cells and expansion of the myeloid line-
ages [86–89]. JAK2 directly phosphorylates BCR-ABL1 
at Y177 and increases BCR-ABL1 protein stability, thus 
enhancing BCR-ABL1 signaling [24, 90]. Moreover, JAK2 
induces mRNA expression of the oncogene c-MYC and 
protects c-MYC protein from degradation [91]. c-MYC 
overexpression plays a critical role in BCR-ABL1 trans-
formation [92] and is a downstream target of activated 
JAK2 in BCR-ABL1-positive cells. Survivin is overex-
pressed in BCR-ABL1-positive cells [93], and BCR-ABL1 
activates c-MYC to induce transactivation of the survivin 
promoter via JAK2/phosphatidylinositol 3-kinase (PI3K) 
signaling pathways [94]. These findings indicate that 
JAK2 controls BCR-ABL1 stability and oncogenic sign-
aling in BCR-ABL1-positive cells [95]. Both JAK2 inhi-
bition and knockdown reduce levels of phosphorylated 
STAT5 (p-STAT5) and inhibit the RAS-PI3K pathway. By 
Fig. 2 Main pathways regulated by the BCR‑ABL1 protein. The downstream pathways regulated by BCR‑ABL1 protein associated with cell survival, 
cell proliferation, cell cycle, cell differentiation, apoptosis, and the microenvironment of leukemia stem cells. Dark violet shapes indicate the kinase; 
lavender pink shapes indicate the proven oncoprotein; blue shapes indicate the proven tumor suppressor protein; and other color shapes indicate the 
proteins existing in normal cells. Red solid lines indicate inhibiting; green solid lines indicate activating. Blue dotted lines indicate that the results need 
further confirmation. Black dotted lines indicate the functions associated with the signaling pathway. JAK2 janus kinase 2, STAT5 signal transducers 
and activators of transcription 5, BCR‑XL B‑cell lymphoma‑extra‑large, CRKL Crk‑like protein, PI3 K phosphatidylinositol 3‑kinase, AKT protein kinase B, 
MDM2 mouse double minute 2 homolog, TP53 tumor protein p53, p21WAF‑1/CIP‑1 cytosolic cyclin‑dependent kinase inhibitor p21, SKP2I S‑phase 
kinase‑associated protein 2 inhibitor, NF‑κB nuclear factor kappa‑light‑chain‑enhancer of activated B cells, IKKβ IKβ kinase, C/EBPα CCAAT/enhancer‑
binding protein α, GATA2 GATA binding protein 2, GRB2 the adaptor protein growth factor receptor‑bound protein 2, SOS son of sevenless, MEK 
mitogen‑activated protein kinase kinase, ERK extracellular signal‑regulated kinases, hnRNP‑E2 poly(rC)‑binding protein E2, FOXO3a forkhead box O3, 
TRAIL TNF‑related apoptosis‑inducing ligand
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contrast, JAK2 inhibition decreases phosphorylated Y177 
(p-Y177) but does not reduce levels of BCR-ABL1, sug-
gesting that the reduction of BCR-ABL1 by JAK2 inhi-
bition is a separate event from phosphorylation of Y177 
[90]. A recent study showed that absence of JAK2 in a 
CML-CP model drastically accelerated disease develop-
ment with increased numbers of WBC counts and severe 
splenomegaly, suggesting that JAK2 inhibits the progress 
of CML [96].
The level of p-STAT3 is higher in CML patients who 
are resistant to imatinib treatment than in patients who 
respond [97]. BCR-ABL1 regulates transcription of 
STAT3 by phosphorylating JAK1/2 and mitogen-acti-
vated protein kinase kinase (MEK) [98]. Both STAT3 
and STAT5a/b are essential for the induction of CML-
like leukemia by BCR-ABL1 and for the maintenance of 
the survival and growth of CML cells [95]. STAT5- or 
STAT3-knockout mice with BCR-ABL1 fail to display a 
CML phenotype and prevent established B-ALL. Addi-
tionally, STAT5, not STAT3, is essential for cell cycle pro-
gression and survival of lymphoid leukemic cells [95]. The 
N-terminal of STAT5a/b plays a key role in B-lymphoid 
transformation [99]. Furthermore, STAT5 is not essen-
tial for normal hematopoiesis [95, 100], which makes it a 
good therapeutic target in Ph-positive leukemia [84, 85].
The PI3K‑AKT‑mTOR pathway
The PI3K-AKT-mammalian target of rapamycin (mTOR) 
pathway is another important downstream cascade in 
Ph-positive leukemia, including CML and ALL. It is able 
to activate c-kit-positive HSCs from the quiescent to the 
proliferative state in BCR-ABL1-positive CML [101]. 
Through a PI3K-AKT-mTOR-independent pathway, 
BCR-ABL1 evades cell cycle arrest by increasing cyto-
solic cyclin-dependent kinase inhibitor p21 (p21WAF-1/
CIP-1), which has been reported to have a pro-survival 
role localizing in cytoplasm [102]. BCR-ABL1 also 
induces S-phase kinase-associated protein 2 (Skp2) 
expression to promote proliferation of CML cells by the 
PI3K-AKT-mTOR pathway [103]. Meanwhile, BCR-
ABL1 increases glucose metabolism and activates mito-
chondrial electron transport chains specifically regulated 
by PI3K-AKT-mTOR in CML cells [104, 105]. Ablation of 
PI3 K prevents BCR-ABL1 leukemogenesis in mice, and 
a dual PI3  K/mTOR inhibitor PI-103 suppresses prolif-
eration of mouse pre-B-ALL more effectively than rapa-
mycin [106]. The dual PI3 K and mTOR small-molecule 
inhibitors are also effective against TKI-resistant BCR-
ABL1 mutant cells in vivo and in vitro [107]. In addition, 
inhibition of PI3K shows synergy with TKI-enhancing 
cytotoxic effects in p210BCR-ABL1-transformed cells, espe-
cially apoptosis [107, 108]. Taken together, these findings 
suggest that the PI3K-AKT-mTOR pathway plays an 
important role in BCR-ABL1-mediated leukemogenesis.
Currently, several PI3K inhibitors are being investi-
gated, and several clinical trials have been completed in 
pediatric ALL [109]. Interestingly, a recent study showed 
that PI3K inhibitors induced global transcriptional repro-
gramming in tumors, with (re)phosphorylation of AKT 
and mTOR, and increased tumor cell motility and inva-
sion [110]. That might explain why PI3K inhibitors were 
not more clinically efficacious in the last 10 years. There-
fore, combining PI3K inhibitors with other therapeu-
tic approaches may be a promising future therapeutic 
strategy.
The MAPK/ERK (RAS/RAF/MEK/ERK) pathway
The RAS/RAF/MEK/extracellular signal-regulated kinases 
(ERK) pathway is a central signal transduction pathway, 
which transmits signals from cell surface receptors to 
nuclear transcription factors. In BCR-ABL1-positive 
leukemia cells, activation of the RAS/RAF/MEK/ERK 
pathway results in uncontrolled proliferation [111–
113]. BCR-ABL1 transduces proliferative signals partly 
through activation of RAS via GRB2/GRB2-associated 
binding protein 2 (GAB2) phosphorylation dependent 
on phosphorylation of Y177 of BCR [31, 114]. Disruption 
of RAS signaling attenuates development of BCR-ABL1-
induced CML-like disease in mice, but most BCR-ABL1-
positive mice with mutant RAS eventually develop 
pro-B-ALL. This indicates that RAS is a critical target of 
BCR-ABL1 in the pathogenesis of CML but not B-ALL 
[115].
Blockage of MEK/ERK elevates cytotoxicity of histone 
deacetylase inhibitors in BCR-ABL1-expressing cells 
resistant to the TKIs gefitinib or imatinib and leads to 
erythroid differentiation [116, 117]. BCR-ABL1 also acti-
vates B-RAF kinase, which is an effector molecule of the 
RAS-related protein RAP1 and a potent activator of the 
MEK/ERK/ELK-1 signaling pathway. Inhibition of RAP1 
activation inhibits the BCR-ABL1-induced activation of 
ERK-1 [113].
Leukemic microenvironment plays a role in promoting 
and maintaining leukemic cell proliferation and surviv-
ability [118]. In addition to BCR-ABL1 kinase activity, 
CML stem cell survival depends on the continuous 
support of the hematopoietic niche [84]. Osteopontin 
(OPN), a component of the stem cell niche, is over-
expressed in BCR-ABL1-expressing cells. BCR-ABL1 
induces OPN overexpression by activating a signaling 
cascade involving RAS, RAF-1, and MAPK, indicating 
that BCR-ABL1 maintains the microenvironment for leu-
kemia stem cells possibly through the RAS/RAF/MEK/
ERK pathway [119].
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Interestingly, oncogene addiction analysis shows that 
due to MEK-dependent negative feedback, JAK2 plays lit-
tle or no role in signal transduction when BCR-ABL1 is 
active. After prolonged BCR-ABL1 inhibition (more than 
8  h), negative feedback is relieved and JAK2 becomes 
critically important as a mediator of STAT5 phospho-
rylation in the downstream pathways [120]. Maintain-
ing negative feedback with oncoprotein inhibition may, 
therefore, best facilitate the effects of target agents.
TRAIL‑induced apoptosis
Tumor necrosis factor (TNF)-related apoptosis-inducing 
ligand-TNFSF10 (TRAIL), a death receptor ligand, is 
down-regulated in BCR-ABL1-positive leukemia [121–
123]. In BCR-ABL1-positive cell lines and primary ALL 
cells, TRAIL induces death-inducing receptor (DR4 and 
DR5)-dependent apoptotic cell death [124]. Treatment 
with imatinib enhances TRAIL-induced apoptosis [125, 
126]. Inducing TRAIL-mediated cell death also inhibits 
cancer cell proliferation and suppresses growth of CML 
xenografts [127].
These results suggest the potential use of recombinant 
TRAIL as a novel therapeutic agent; they also suggest the 
possible contribution of endogenously expressed TRAIL 
in immunotherapy against BCR-ABL1-positive leukemia.
C/EBPα‑mediated differentiation
CCAAT/enhancer-binding proteins (C/EBPs) are tran-
scription factors that regulate normal myelopoiesis as 
well as myeloid disorders. BCR-ABL1 suppresses C/EBPα 
mRNA levels via the induction of the mitogen-activated 
protein kinases-poly(rC)-binding protein E2 (MAPK-
hnRNP-E2) pathway [128–130]. Disruption of C/EBPα 
blocks the transition from common myeloid to granu-
locyte-monocyte progenitor cells [131]. The failure of 
myeloid precursors to differentiate into mature granulo-
cytes is a unique characteristic of clinical progression from 
CML-CP to CML-BC. C/EBPα expression is reduced in 
BCR-ABL1-expressing cell lines and CML-BC cells. Loss 
of miR-328 in CML-BC also reduces expression of C/EPBα 
[132]. Meanwhile, phosphorylation at serine 21 of the C/
EBPα protein is associated with differentiation effects in 
K562 cells [133]. Furthermore, C/EBPα deregulation and 
neutrophilic differentiation by BCR-ABL1 are reversed by 
imatinib [134]. The gene profile shows that activation of C/
EBPα induces the expression of cell cycle- and apoptosis-
related genes and enhances imatinib-induced apoptosis of 
K562 cells [135]. Restoration of C/EBPα expression induces 
terminal granulocytic differentiation and inhibits prolifera-
tion of leukemia cells in vitro and in vivo [136–138]. More-
over, the effects of C/EBPα in p210BCR-ABL1-expressing cells 
depend partly on transcriptional repression of c-MYC and 
GATA-2 [139]. However, absence of C/EBPα results in loss 
of myeloid identity in transgenic mice with BCR-ABL1-
induced CML-like disease and, interestingly, causes eryth-
roleukemia instead, suggesting that CEBPα is essential for 
BCR-ABL1-positive CML [140].
Ectopic expression of C/EBPα in primary human BCR-
ABL1-positive B-ALL cells induces macrophage-like 
cells, which are unable to establish disease in xenograft 
hosts [141]. Epigenetic studies show that aberrant meth-
ylation in the CpG island of the promoter region of C/
EBPα is a common event in CML, suggesting that regu-
lating methylation of C/EBPα could be a new therapeutic 
direction for treating Ph-positive leukemia [142].
Autophagy
Autophagy can be manipulated for a better therapy on 
AML by inducing cooperation with apoptosis and differen-
tiation [143]. Also, autophagy presents a potential target in 
BCR-ABL1-positive leukemia, particularly in TKI-resist-
ant types [144–146]. Disruption of autophagy is a new 
strategy to treat imatinib-resistant CML patients. Pharma-
cologic or genetic inhibition of the Hedgehog pathway can 
markedly induce autophagy in BCR-ABL1-positive CML 
cells. Inhibition of both Hedgehog pathway and autophagy 
may be a potent new strategy to overcome drug resist-
ance in CML [147]. Importantly, BCR-ABL1 suppresses 
apoptosis as well as autophagy, resulting in low basal lev-
els of autophagy in BCR-ABL1-transformed cells. Treat-
ment of BCR-ABL1-positive cells in  vitro with chemical 
inhibitors of autophagy or by deletion of the autophagy-
related 3 (Atg3) gene induces cell death. In a cell transfer 
model in  vivo, Atg3 deletion also prevented BCR-ABL1-
mediated leukemogenesis [148]. Moreover, the therapeu-
tic drug arsenic trioxide (As2O3) targeted BCR-ABL1 for 
autophagy degradation via a p62/the gene encoding p62 
(SQSTM1)-dependent mechanism, which is mediated 
localization of the oncoprotein to the autolysosomes [149].
In conclusion, BCR-ABL1-positive cells particularly 
depend on autophagy for leukemogenesis, and regulation 
of autophagy may be a therapeutic approach for BCR-
ABL1-positive leukemia.
Genomic instability
Genomic instability is an essential factor of tumorigen-
esis for both leukemias and solid tumors. Chromosomal 
translocations generate the aberrant fusion TKs, such 
as BCR-ABL1, Ets variant gene 6-ABL1 [TEL(ETV6)/
ABL1], TEL(ETV6)/JAK2, and TEL-platelet-derived 
growth factor beta receptor [TEL(ETV6)/PDGFβR], 
which induce hematologic malignancies [150]. BCR-
ABL1-positive cells contain elevated numbers of DNA 
double-strand breaks (DSBs) and show stimulation of the 
single-strand annealing (SSA) repair process [151–153]. 
The WRN gene (mutated in Werner syndrome) encodes 
Page 8 of 15Kang et al. Chin J Cancer  (2016) 35:48 
a helicase required for processing DSB ends during the 
repair. BCR-ABL1 enhances the expression and increases 
the nuclear localization of WRN to promote survival and 
genomic instability [154].
Prolonged expression of the p210BCR-ABL1 transcript 
was associated with development of aneuploidy and 
complex chromosomal translocations in the mouse 
model [155]. Transgenic mice expressing p190BCR-ABL1 
developed karyotypic abnormalities, most commonly tri-
somies involving chromosomes 12, 14, or 17, alone or in 
combination [18].
A recent study using a whole transcriptome array 
showed that genes such as dipeptidyl peptidase-4 (DPP4), 
interleukin-2 receptor alpha (IL2RA), protein tyros-
ine phosphatase, receptor type D (PTPRD), calcium 
channel, voltage-dependent, L type, alpha 1D subunit 
(CACNA1D), interleukin 1 receptor accessory protein 
(IL1RAP), solute carrier family 4 (SLC4A4), and potas-
sium channel, subfamily K, member 5 (KCNK5) were 
up-regulated in BCR-ABL1-positive CML. This study 
found that these genes play key roles in proliferation, 
differentiation, and molecular pathways in HSCs [156]. 
Accumulation of additional cytogenetic and molecular 
abnormalities also contributes to blast transformation 
and progression [157–159]. BCR-ABL1 and genomic 
instability are currently considered to be a complex part-
nership in leukemogenesis, suggesting that BCR-ABL1 
itself leads to genomic instability independent of its leu-
kemogenic effect [20].
The Ph rarely appears with other genetic abnormali-
ties in CML-CP. However, in Ph-positive B-ALL, AML, 
MPAL, and CML-AP and CML-BP, deletions involv-
ing immunoglobulin heavy chain (IGH), T-cell receptor 
(TCR), encoding the transcription factor IKAROS fam-
ily zinc finger protein 1 (IKZF1), and cyclin-dependent 
kinase inhibitor 2 (CDKN2A/B) are common [66]. A 
recent study showed that the BCR-ABL1 fusion gene 
could be a prenatal and possibly initiating genetic event 
in Ph-positive childhood ALL and that variation in other 
genes is a secondary and probably postnatal event in 
these cases [160]. Common gene abnormalities found in 
Ph-positive leukemia are discussed in Table 1.
IKZF1 mutation
IKZF1, located on chromosome 7p12, is a regulator of 
lymphocyte differentiation. Wild-type IKAROS prevents 
stemness properties and has tumor suppressor activ-
ity in BCR-ABL1-initiated leukemia [161]. BCR-ABL1 
and IKZF1 mutations are strongly linked: somatic muta-
tions in IKZF1 are present in 70%–83% of Ph-positive 
ALL cases; approximately 90% are deletions, and 10% 
are point mutations [162]. Deletion of IKZF1 has also 
been identified as an acquired lesion at transformation 
from CML-CP to lymphoid CML-BC but never in mye-
loid CML-BC or AML with Ph [163]. In addition, loss 
of IKZF1 predicts a poor prognosis in patients with Ph-
positive leukemia [164]. Disruption of IKAROS activity 
in primitive CML-CP cells can mimic myeloid disease 
Table 1 Recurrent genomic abnormalities in Philadelphia chromosome (Ph)‑positive leukemia
IKZF1 transcription factor IKAROS family zinc finger protein 1, PAX5 paired box 5, EBF1 early B-cell factor 1, CDKN2A/B cyclin-dependent kinase inhibitor 2, IG 
immunoglobulin, TCR T-cell receptor, BTG1 B-cell translocation gene 1, IGHV immunoglobulin heavy chain variable region, IGHG2M immunoglobulin heavy constant 
gamma 2, IGLL1 immunoglobulin lambda-like polypeptide 1, TCRA T-cell receptor alpha locus, ALL acute lymphoblastic leukemia, CML-BC chronic myeloid leukemia 
blast crisis, AML acute myeloid leukemia, MPAL mixed-phenotype acute leukemia, BCP-ALL B-cell precursor ALL
Genomic abnormality Location Status Ph‑positive leukemia Frequency Reference(s)
IKZF1 7q12.2 Deletion ALL 50%–83% [162, 164]
Deletion Lymphoid CML‑BC 73%–75% [163, 180]
PAX5 9p13 Deletion ALL 33%–51% [171, 172, 180]
Deletion Lymphoid CML‑BC 58.3% [180]
EBF1 5q34 Deletion ALL 14% [198]
CDKN2A/B 9p13‑p23.1 Deletion AML 50% [66]
Deletion MPAL 33.3% [66]
Deletion ALL 53.5% [163, 164]
Deletion Lymphoid CML‑BC 58.3%–69% [180]
IG 14q32.33 IGHV/IGHG2 M deletion Lymphoid CML‑BC 66%–100% [66, 163, 180]
22q11.2 IGLL1 deletion AML 66.7% [66]
TCR 14q11.2/7p14.1 TCRA/B/D deletion AML/MPAL 66.7% [66]
14q11.2 TCRA deletion Lymphoid CML‑BC 74% [66, 180]
BTG1 12q21.33 Deletion BCP‑ALL 11%–31.3% [176]
Deletion MPAL 33.3% [176]
Deletion CML‑BC (B‑lineage) 33.3% [176]
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progression (CML-AP), revealing that loss of IKAROS 
is a frequent step and potential predictor of BCR-ABL1-
positive CML-AP/BC [162]. The IKAROS-6 (IK6) is pro-
duced by an in-frame deletion of exons 4–7 of IKZF1, 
which deletes the DNA-binding domain and leads to 
cytosolic accumulation of the mutant protein. The muta-
tions associated with a more profound reduction in IKA-
ROS function (bi-allelic deletion and IK6) are particularly 
common in Ph-positive ALL [165].
In addition, loss of IKZF1 is recurrent in pediatric 
AML and may be a determinant of oncogenesis in AML 
with monosomy 7 [166]. Sequencing of IKZF1 deletion 
breakpoints suggests that aberrant recombination acti-
vating gene (RAG)-mediated V(D)J recombination is 
responsible for the deletions [167].
PAX5 and EBF1 mutation
The paired box 5 (PAX5) and early B-cell factor 1 (EBF1) 
are transcription factors that are expressed specifically 
during B-cell development and control lineage iden-
tity and commitment [168–170]. Recurrent deletions of 
PAX5 and EBF1 occur in approximately 50% and 14% of 
Ph-positive ALL cases, respectively [163, 168, 171]. In 
contrast to BCR-ABL1-negative ALL, no point mutations 
of PAX5 have been found, suggesting that deletions are 
the main mechanism of inactivation of PAX5 in BCR-
ABL1-positive ALL [172]. EBF1 co-regulates target genes 
with PAX5. In mouse models, loss of PAX5 or EBF1 leads 
to a differentiation block at the pro- to pre-B-cell stage, 
resulting in B-cell precursor leukemia (BCP-ALL) [170, 
173]. Complete loss of PAX5 and EBF1 is apparently a 
secondary event and is significantly associated with BCR-
ABL1 [171].
BTG1 deletion
The B-cell translocation gene 1 (BTG1) on chromo-
some 12q21.33 is highly conserved and belongs to an 
antiproliferative gene family that regulates cell growth, 
differentiation, and angiogenesis [174, 175]. BTG1 dele-
tion occurs in 11%–31.3% of BCP-ALL cases, in 33.3% of 
MPAL cases, and in 33.3% of CML-BC (B-lineage) cases 
[176]. Eight distinct deletions of different sizes within the 
second exon of BTG1 have been identified in BCP-ALL, 
resulting in the expression of truncated BTG1 transcripts 
[177]. Loss of BTG1 expression also causes glucocorti-
coid (GC) resistance both by reducing glucocorticoid 
receptor (GR) expression and by controlling GR-medi-
ated transcription in ALL [178]. It suggests that BTG1 
deletions may act as “drivers” of leukemogenesis in BCP-
ALL, MPAL, and lymphoid CML-BC (B-lineage) with Ph. 
BTG1 overexpression inhibits proliferation and invasion 
and induces G2/M arrest, differentiation, senescence, and 
apoptosis in xenograft models of gastric cancer. Restoring 
BTG1 might reverse phenotypes and be a potential target 
for gene therapy of Ph-positive leukemia [179].
IGH and TCR deletion
The deletions of 4 chromosomal regions, 7p12–14, 
9p21–24, 14q11.2, and 14q32.33, are found recurrently 
in Ph-positive leukemia. The deletions of immunoglob-
ulin heavy chain (IgH) genes and TCRα/β/γ genes are 
restricted to the four chromosomal regions. Most com-
mon deletions include immunoglobulin heavy chain 
variable region (IGHV), immunoglobulin heavy constant 
gamma 2 (IGHG2  M), and T-cell receptor alpha locus 
(TCRA). Deletion within both IGH and TCR genes is a 
characteristic of lymphoid CML-BC with Ph; none of 
these genome losses is detected in CML-CP or myeloid 
CML-BC samples [180]. Deletions within chromosomes 
7 and 9, including IKZF1 and CDKN2a/b genes, are also 
frequently accompanied by IGH and TCR gene deletion 
in Ph-positive BP-ALL [66], indicating that deletion of 
the IGH and/or TCR gene region is obligatory for the 
development of a malignant clone with a lymphoid phe-
notype. Interestingly, Ph-positive AML also possesses 
deletions of immunoglobulin (IG) and TCR genes but 
involving immunoglobulin lambda-like polypeptide 1 
(IGLL1, 22q11.2) and TCRA/B/D (14q11.2 and 7p14.1), 
respectively. The above studies suggested that different 
parts of the deletion with IG and TCR genes might result 
in different phenotypes of leukemia [19, 66, 163].
Therapeutic resistance and disease progression 
in Ph‑positive leukemia patients
Compared with CML-CP patients, imatinib responses are 
much less durable in patients with CML-AP/BC or ALL 
[8–10]. Compelling research suggests that a population 
of cancer stem cells (CSCs) is responsible for therapeu-
tic resistance and disease progression. BCR-ABL1-posi-
tive stem cells persist in CML patients despite prolonged 
treatment with imatinib [181, 182]. Primitive, quiescent, 
Ph-positive stem cells (CD34+CD38–) from patients with 
CML are insensitive to imatinib in  vitro [183]. Consist-
ently, the BCR-ABL1 expression in persistent leukemic 
stem cells could explain innate resistance to imatinib and 
to other TKIs [184].
In CML patients with TKI resistance, relapse or evolv-
ing to blast crisis, BCR-ABL1 kinase mutations (M237I, 
L248V, Q252E, Y253H, D276G, G321E, V304A, M351T, 
T315 I, E352G, Y353G, E373G, and T389A) can be 
detected in stem cells [185, 186]. Mutations were found 
in 27% of CML-CP patients, 52% of CML-AP patients, 
75% of myeloid blast crisis patients, and 83% of lymphoid 
blast crisis/Ph-positive ALL patients [187]. Thirty percent 
of patients with primary resistance and 57% of patients 
with acquired resistance were associated with these 
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mutations [187]. Studies have confirmed that the muta-
tions were the potential source of resistance and relapse 
[185]. The following mutations are involved in therapu-
tic resistence and disease progression [188]: (1) contact 
residues (such as T315) by impeding inhibitor access or 
eliminating critical hydrogen bonds; (2) the ATP-binding 
loop (such as L248V) by preventing Abl from adopt-
ing the specific conformation required for high-affinity 
imatinib binding; and (3) regulatory motifs (such as the 
activation loop) by stabilizing an active conformation 
that is inaccessible to imatinib.
Recent studies showed that inhibition of heat shock 
protein 90 (Hsp90) decreased the number of leukemia 
stem cells, caused BCR-ABL protein degradation by the 
ubiquitin-proteasome pathway, and prolonged survival 
of mice with CML induced by BCR-ABL-T315I [189, 
190]. Many novel Hsp90 inhibitors have entered into 
clinical trials, the results of which are encouraging [190]. 
This anti-Hsp90 strategy in treating CML patients, espe-
cially with TKI resistance, has a good application pros-
pect. Another study showed that some alkyne-containing 
pyrazolopyrimidines can inhibit not only Abl(T315I) 
in vitro but also Bcr-Abl(T315I) in cells, suggesting that 
these pyrazolopyrimidines can serve as lead compounds 
for targeted therapy to overcome drug resistance of CML 
[191]. Also, one third-generation TKI, ponatinib, has 
been proven against the drug resistance including the 
T315I mutation. X-ray crystallographic analysis revealed 
that ponatinib inactivated T315I Bcr-Abl mutated kinase 
by conformational alteration [192].
In brief, a quiescent population of leukemia stem cells 
with or without BCR-ABL1 kinase domain mutations is 
responsible for drug resistance [11].
Conclusion leukemogenesis is an outcome of the 
Ph combined with other genetic variations
Expression of BCR-ABL1 (p210 transcript) has been 
detected at very low levels in the peripheral blood cells 
of some healthy individuals but not in umbilical cord 
blood cells [193]. In addition, BCR-ABL1-specific T cells 
are detected in healthy donors and in CML patients after 
allogeneic stem cell transplantation [194]. These results 
indicate that normal cells evolve progressively to a neo-
plastic state, and they may acquire a succession of genetic 
abnormalities and gain the ability to maintain prolifera-
tion, inhibit differentiation, and resist cell death [195].
The Ph bearing the BCR-ABL1 fusion gene is the key 
initiator of different phenotypes of leukemia with diverse 
prognoses. The translocation leads to persistent TK acti-
vation and genomic instability during leukemogenesis. 
Disorders in multiple signaling pathways and genetic 
abnormalities combined with the Ph are essential for the 
evolution of different types of leukemia; however, why 
cells possessing the Ph should evolve specifically into 
CML, AML, ALL, or MPAL is currently unclear and 
under investigation. Evidence shows that there are charac-
teristics exclusive to specific leukemias, including deletion 
of BTG1 in B-cell leukemia, loss of IKZF1 with monosomy 
7 in AML, and deletions involving IGH, TCR, IKZF1, and 
CDKN2A/B in CML-AP/CP. Greater understanding of 
leukemogenesis and the effect of treatment on clonal evo-
lution will provide novel insights into the design of future 
therapeutic strategies for Ph-positive leukemia [196, 197].
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